1.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18527, NCT00121836
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 97-02-12, NCT00686322
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: E-1193, NCCTG-923252, SWOG-9332, E-10292, E1193
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
|
|
5.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CA139-384, NCT00337532
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 40 to 75 Sponsor: Other Protocol IDs: Hamamatsu 18-66, NCT00752115
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: BR18, CAN-NCIC-BR18, BMS-CA161-003, CDR0000068153, NCT00006229
|
|
8.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: BR24, CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B, CDR0000450850, NCT00245154
|
|
9.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068744, E4599, CALGB-E4599, ECOG-4599, NCT00021060
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UCL/09/105, Funder reference (academic), Funder reference (industry), 2009-017171-13, NCT01196741
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2007-001346-41, ISRCTN68510403, NCT00532194
|
|
12.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: INRC-PITCAP, EU-20202, INRC-ITA, NCI-V01-1665, NCT00039039
|
|
13.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: THERADEX-B00-1370, BMS-TAX/MEN.13, NCT00025688
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENENTECH-OSI2298g, MSKCC-01122, NCT00029016
|
|
15.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-P-0014, RTOG-DEV-1028, ECOG-RTOG-P-0014, CALGB-RTOG-P-0014, SWOG-RTOG-P-0014, NCT00030654
|
|
16.
|
Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-48, BMC-C-7093-49, UCLA-0301086
|
|
17.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CRC-TU-TANGO, EU-20058, NCT00039546
|
|
18.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40101, NCT00041119
|
|
19.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-111
|
|
20.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: CAN-NCIC-OV9, NCI-V91-0148, OV9
|
|
21.
|
Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: GOG-132, GOG-0132
|
|
22.
|
Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: GOG-0114, EST-GO114, SWOG-9227
|
|
23.
|
Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: GOG-134, E-GO134, NCCTG-926151, SWOG-9238, INT-0134, G0134
|
|
24.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-93-C-0153I, NCI-MB-318, NCI-T93-0041N, T93-0041
|
|
25.
|
Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: E-5592, E5592
|